CROSSJECT SA EO -10
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more
CROSSJECT SA EO -10 (74C) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CROSSJECT SA EO -10 (74C) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CROSSJECT SA EO -10 - Net Assets Trend (None–None)
This chart illustrates how CROSSJECT SA EO -10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CROSSJECT SA EO -10 (None–None)
The table below shows the annual net assets of CROSSJECT SA EO -10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CROSSJECT SA EO -10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CROSSJECT SA EO -10 Competitors by Market Cap
The table below lists competitors of CROSSJECT SA EO -10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PKP Cargo S.A.
WAR:PKP
|
$99.35 Million |
|
DIC Asset AG
PINK:DDCCF
|
$99.35 Million |
|
Tung Thih Electronic Co Ltd
TWO:3552
|
$99.42 Million |
|
Globe Union Industrial Corp
TW:9934
|
$99.44 Million |
|
Baader Bank Aktiengesellschaft
F:BWB
|
$99.32 Million |
|
Sabaf S.p.A
STU:SM5
|
$99.29 Million |
|
Bravo Mining Corp.
OTCQX:BRVMF
|
$99.26 Million |
|
Kits Eyecare Ltd
PINK:KTYCF
|
$99.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CROSSJECT SA EO -10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CROSSJECT SA EO -10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CROSSJECT SA EO -10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CROSSJECT SA EO -10's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $9,394,036,854
- Average return on equity (ROE) among peers: 4.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CROSSJECT SA EO -10 (74C) | €- | N/A | N/A | $99.33 Million |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $213.74 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $475.06 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $32.92 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $217.64 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $658.78 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $783.58 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.63 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.27 Billion |